Ashley Ajlouny
Pulmonary Disease · Novi, MINPI 1629621248
Payments from drug & device makers
What this record shows
Inspire Medical Systems, Inc. accounts for 68.6% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $1,756, 7.8 times the $225 reported in 2022.
Across 39 payments — averaging $76.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- Grifols USA, LLC$177
- GSK$162
- Pulmonx Corporation$135
- United Therapeutics Corporation$110
- Regeneron Healthcare Solutions, Inc.$79
- plus $277 from 8 others
What the payments were for
- Travel & lodging$1,40347%
- Food & beverage$1,58653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 12 | $2,050 |
| Grifols USA, LLC | 3 | $177 |
| GSK | 4 | $162 |
| Pulmonx Corporation | 1 | $135 |
| United Therapeutics Corporation | 1 | $110 |
| Regeneron Healthcare Solutions, Inc. | 4 | $79 |
| ANI Pharmaceuticals, Inc. | 2 | $54 |
| Boehringer Ingelheim | 2 | $49 |
| AstraZeneca | 3 | $46 |
| Viatris Specialty LLC | 2 | $41 |
| Insmed, Inc. | 1 | $29 |
| Electromed, Inc. | 2 | $21 |
| Penumbra, Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$1,884
- ZEPHYR DELIVERY CATHETER$135
- ZEPHYR ENDOBRONCHIAL VALVE$135
- PULMONX CHARTIS TABLET CONSOLE$135
- CHARTIS CATHETER$135
- Xembify$125
- AREXVY$108
How this compares
$2,989 in reported general payments places this provider in the 60th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $37,560 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $22,029 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $12,423 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $2,399 |
| Montelukast Sodium | 14 | $235 |
| Azithromycin | 11 | $201 |
| Fluticasone Propionate | 13 | $162 |
| Prednisone | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $162 | $37,56048 claims |
| AstraZenecaBreztri Aerosphere | $46 | $22,02932 claims |
| Boehringer IngelheimStiolto Respimat | $49 | $12,42323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Novi
- Bradley RowensNovi$26K
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
- Podduturu ReddyPort Huron$324K
- Samuel AllenTroy$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.